Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma

Blockade of the immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including melanoma and renal cell carcinoma (RCC). Characteristic markers such as the presence of tumor inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Marmarelis, Melina E., Davis, Meredith R., Sethi, Nilay S., Krajewksi, Katherine M., McKay, Rana R., Choueiri, Toni K., Ott, Patrick A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837591/
https://www.ncbi.nlm.nih.gov/pubmed/27099755
http://dx.doi.org/10.1186/s40425-016-0129-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837591/
https://www.ncbi.nlm.nih.gov/pubmed/27099755
http://dx.doi.org/10.1186/s40425-016-0129-x

Ejemplares similares